Ann Collie, DO
Endocrinology, Diabetes & Metabolism · Peru, INNPI 1518096767
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $829 and has fallen 70.4% since, to $245 in 2025.
Across 241 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$509
- Novo Nordisk$431
- Boehringer Ingelheim$323
- Xeris Pharmaceuticals, Inc.$203
- Sanofi-aventis U.S. LLC$177
- AbbVie$173
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,58099%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $509 |
| Novo Nordisk | 52 | $431 |
| Boehringer Ingelheim | 20 | $323 |
| Xeris Pharmaceuticals, Inc. | 12 | $203 |
| Sanofi-aventis U.S. LLC | 12 | $177 |
| AbbVie | 10 | $173 |
| Corcept Therapeutics | 9 | $160 |
| Amgen(2 entities) | 10 | $159 |
| Insulet Corporation | 8 | $151 |
| Tandem Diabetes Care, Inc. | 10 | $150 |
| Abbott | 7 | $147 |
| Novartis | 8 | $139 |
| AstraZeneca(2 entities) | 8 | $136 |
| Bayer | 7 | $133 |
| Dexcom, Inc. | 7 | $105 |
| Amneal Pharmaceuticals LLC | 6 | $100 |
| Amarin Pharma, Inc. | 5 | $83 |
| Cequr Corporation | 2 | $59 |
| Merck | 4 | $52 |
| GRT US Holding, Inc. | 3 | $38 |
| Companion Medical, Inc. | 2 | $37 |
| IBSA Pharma Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Medtronic | 1 | $17 |
| Lifescan, Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,606 in reported general payments places this provider in the 65th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 14 | $282,375 |
| OzempicSemaglutide | 156 | $196,331 |
| MounjaroTirzepatide | 121 | $159,951 |
| Tresiba Flextouch U-200Insulin Degludec | 105 | $140,198 |
| JardianceEmpagliflozin | 120 | $125,923 |
| TrulicityDulaglutide | 84 | $101,564 |
| FarxigaDapagliflozin Propanediol | 27 | $35,614 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $31,772 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $23,179 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $13,837 |
| SynthroidLevothyroxine Sodium | 116 | $11,306 |
| Humalog Kwikpen U-100Insulin Lispro | 33 | $10,498 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $8,950 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $8,806 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $7,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $160 | $282,37514 claims |
| Lilly USA, LLCMounjaro, Trulicity | $509 | $261,515205 claims |
| Novo NordiskOzempic | $431 | $196,331156 claims |
| Boehringer IngelheimJardiance | $323 | $125,923120 claims |
| AstraZenecaFarxiga | $136 | $35,61427 claims |
| AbbVieSynthroid | $173 | $11,306116 claims |
| Sanofi-aventis U.S. LLCLantus | $177 | $5,11613 claims |
| IBSA Pharma Inc.Tirosint | $32 | $3,02111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $100 | $1,539167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Peru
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.